Abstract-Antagonists of the mineralocorticoid receptor improve morbidity and mortality in patients with severe heart failure. However, the cell types involved in these beneficial effects are only partially known. The aim of this work was to evaluate whether genetic deletion of mineralocorticoid receptors in mouse cardiomyocytes or fibroblasts in vivo is cardioprotective after chronic left ventricular pressure overload. After transverse aortic constriction, mice deficient in myocyte mineralocorticoid receptors but not those deficient in fibroblast mineralocorticoid receptors were protected from left ventricular dilatation and dysfunction. After pressure overload, left ventricular ejection fraction was significantly higher in mice lacking myocyte mineralocorticoid receptors (70.2Ϯ4.4%) as compared with control mice (54.3Ϯ2.5%; PϽ0.01). Myocyte mineralocorticoid receptor-deficient mice showed mild cardiac hypertrophy at baseline, contributing to reduced left ventricular wall tension at baseline and after pressure overload. Cardiac levels of phospho-extracellular signal-regulated kinase 1/2 were higher in myocyte mineralocorticoid receptor-deficient mice than in control mice after pressure overload. Neither fibroblast nor myocyte mineralocorticoid receptor ablation altered the development of cardiac hypertrophy or fibrosis after pressure overload. Both mineralocorticoid receptor mutant mouse strains developed similar degrees of myocyte apoptosis, proinflammatory gene expression, and macrophage infiltration after pressure overload. Thus, mineralocorticoid receptors in cardiac myocytes but not in fibroblasts protect from cardiac dilatation and failure after chronic pressure overload. (Hypertension. 2011;57:00-00.) • Online Data Supplement
P
harmacological inhibition of the mineralocorticoid receptor (MR) by antagonists like spironolactone or eplerenone has improved the clinical outcome in human heart failure. [1] [2] [3] Activation of the renin-angiotensin-aldosteronesystem has been shown to induce cardiac remodeling in numerous animal studies. 4, 5 MR antagonists have been demonstrated to reduce interstitial and perivascular fibrosis in the heart. 6 -8 However, additional actions have been proposed to contribute to the cardioprotective effects of MR antagonists, including antihypertrophic, anti-inflammatory, and antiarrhythmic effects. 9 Despite the clinical benefit of MR antagonists, their cellular target(s) and the precise mechanism of action have not yet been fully uncovered. Several mouse models have been generated to address these questions. For example, overexpression of MRs under control of the human MR promoter 10 or conditional tetracycline-regulated cardiac myocyte-specific MR overexpression 11 resulted in detrimental effects, including cardiac hypertrophy or severe arrhythmia, respectively. Enhanced MR signaling by transgenic expression of the 11␤-hydroxysteroid dehydrogenase type 2 caused severe cardiomyopathy, fibrosis, and mortality, all of which could be partially improved by treatment with the MR antagonist eplerenone. 12 Transgenic overexpression of aldosterone synthase in cardiac myocytes in vivo caused coronary dysfunction but prevented the detrimental effects of experimental diabetes mellitus on cardiac capillary density. 13, 14 Immune cells may play an important role for cardiac pathophysiology, because MR ablation in monocytes and macrophages prevented the development of hypertension and cardiac fibrosis after chronic deoxycorticosterone or N G -nitro-L-arginine methyl ester/angiotensin II treatment. 15, 16 MR is expressed in both major cardiac cell types, cardiac myocytes and fibroblasts. To evaluate the functional relevance and to determine its importance for the development of cardiac hypertrophy, fibrosis, and dysfunction, we have generated mouse models with cell type-specific deletion of the MR gene in cardiac myocytes and fibroblasts, respectively. Ablation of myocyte but not fibroblast MRs protected from left ventricular (LV) dilatation and functional deterioration after chronic pressure overload without affecting cardiac fibrosis.
Methods
Additional materials and methods are mentioned in the online Data Supplement (please see http://hyper.ahajournals.org).
Generation of MR Mutant Mice
Cardiomyocyte-specific inactivation of the MR gene was achieved using a conditional MR allele (MR flox ) 17 and mice expressing Cre recombinase under control of the atrial myosin light chain gene promoter (MLCCre) 18, 19 or the collagen 1␣2 promoter (COLCre), 20 respectively. All of the animal procedures were approved by the responsible animal care committees (Regierungspräsidium Freiburg, Karlsruhe/Germany), and they conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (publication No. 85-23, revised 1996). The "control" genotype includes mice with 1 or 2 floxed MR alleles that do not carry a Cre transgene. "Wild-type" refers to C57BL/6N mice.
Transverse Aortic Constriction
Male mice (8 to 10 weeks old) were anesthetized with 2% (vol) isoflurane in oxygen. After thoracotomy, a 7.0 silk suture was placed around a 27-G hypodermic needle to constrict the transverse aorta (TAC). 21, 22 TAC mice were compared with nonoperated mice at baseline ("basal").
Hemodynamic Measurements and Echocardiography
For LV catheterization with a 1.4-F pressure-volume catheter, mice were anesthetized with isoflurane (2% vol/vol in O 2 ) and placed on a 37°C table. 21, 22 Echocardiography was performed at baseline and every 2 weeks for 20 weeks after transverse aortic constriction using a Vivid 7 Dimension (GE Healthcare) echocardiograph equipped with a 14-MHz transducer. Ejection fraction was calculated as described. 23 Wall stress was determined from echocardiography and pressure-volume catheterization data. 24 
Statistical Analysis
Data were analyzed using 2-way ANOVA followed by Bonferroni post hoc tests or Student t test, respectively. A P value of Ͻ0.05 was considered statistically significant. Results are displayed as meanϮSEM.
Results

Generation and Validation of MR Deletion in Cardiac Myocytes
To inactivate the MR gene specifically in cardiac myocytes in vivo, mice harboring a conditional MR allele (MR flox ) 17, 25 were crossed with myosin light chain gene promoter Cre mice (MLCCre) 18, 19 ( Figure S1A , available in the online Data Supplement at http://hyper.ahajournals.org). Cre-mediated recombination of the conditional MR flox allele resulted in deletion of exon 3 of the MR gene, leading to ablation of MR protein expression in MR MLCCre mice.
In cardiac myocyte fractions isolated from MR MLCCre mice, MR mRNA expression was reduced to 11.6Ϯ7.7% of the level in control myocyte preparations ( Figure S1B and S1C). In contrast, MR expression in cardiac nonmyocyte fractions did not differ between both genotypes ( Figure S1C ). To validate cell-type and organ specificity of the gene targeting strategy, MR expression was determined in the hippocampus and kidney, which contained similar or higher MR mRNA levels, respectively ( Figure S2 ). Immunohistochemical analysis of brain and kidney sections did not reveal any alteration of MR protein expression in these tissues in MR MLCCre mice ( Figure S1D and S1E). However, MR protein expression in control hearts was too low for specific detection by immunohistochemistry (data not shown).
Cardiac Function of MR MLCCre Mice
Blood pressure and LV function of MR MLCCre mice were assessed by direct aortic and cardiac catheterization and by echocardiography ( Figure 1 and Tables S1 and S2). Systolic and diastolic pressures, heart rate, and LV contractility and relaxation did not differ among untreated MR MLCre , MLCCre, and control animals (Table S1 ).
After TAC, mortality did not differ between genotypes (data not shown). Mean trans-stenotic pressure gradient, as determined by pulsed-wave Doppler investigation, was 32.5Ϯ2.9 mm Hg in control mice and 31.8Ϯ2.6 mm Hg in MR MLCCre mice (Pϭ0.86; Figure 1A ). At baseline, no differences in ejection fraction and LV ID in diastole were observed between genotypes ( Figure 1B , 1D, and 1E). A significant decline in ejection fraction after TAC was observed in control mice but not in MR MLCCre mice ( Figure 1D ). LV inner diastolic diameter and wall tension increased in control mice after TAC but remained unchanged in MR MLCCre mice (Figure 1B, 1C, and 1E and Table S2 ).
Cardiac Hypertrophy Induced by TAC in MR MLCCre Mice
Ventricular weight and cardiac weight to body weight or tibia length indexes were higher in MR MLCCre mice at baseline as compared with control mice (Figure 2A and 2B; Table S1 ). Transgenic expression of Cre recombinase alone (MLCCre) did not affect the ventricular weight indexes (Table S1 ). After TAC ventricular weight and ventricular weight indexes increased to similar values in both genotypes (Figure 2A and 2B; Table S1 ). A small but significant increase in LV cardiac myocyte cross-sectional area was already apparent at baseline in MR MLCCre mice ( Figure 2C through 2F). After TAC, myocyte cross-sectional areas increased to similar levels in MR MLCCre and control mice ( Figure 2E and 2F). Myocyte apoptosis did not differ between genotypes at baseline or after TAC ( Figure 2G and 2H).
Transcriptome Analysis and Increased Extracellular Signal-Regulated Kinase 1/2 Signaling in MR MLCCre Mice
Microarray expression profiling of mRNA isolated from total ventricular tissue revealed significant differences in gene expression between MR MLCCre and control mice at baseline and after TAC ( Figure 3A and Table S3 ). Expression of the MR target gene serum glucocorticoid-regulated kinase (Sgk1) in ventricular tissue was induced by TAC but did not differ between genotypes ( Figure S3A ). However, in cell typespecific analyses, Sgk1 expression was reduced in untreated myocytes but not in nonmyocytes isolated from MR MLCCre mice compared with control mice ( Figure 3B and Figure  S3B ). Aldosterone stimulated Sgk1 expression in control but not in MR-deficient myocytes, providing additional evidence for specific and efficient MR ablation in cardiac myocytes ( Figure 3B ). Similarly, in MR-deficient myocytes, mRNA expression of the MR target gene Adamts1 (a disintegrin-like and metallopeptidase with thrombospondin type 1 motif 1) was reduced to 28.5Ϯ7.4% of the level in control myocytes. Expressions of the atrial natriuretic peptide precursor gene (Nppa) and the ␤-isoform myosin heavy chain gene (␤-MHC) were increased in MR MLCCre versus control hearts at baseline and after TAC ( Figure 3C and 3D ). Protein levels of phosphorylated p70S6 kinase, Akt, extracellular signal-regulated kinase (ERK) 1/2, p38 mitogen-activated protein kinase ( Figure 3E ), and Stat3 and JNK1,2,3 (not shown) did not differ between genotypes at baseline. However, after TAC, levels of phosphorylated ERK1 and ERK2 were significantly increased in MR MLCCre versus control mice ( Figure 3F ). To identify potential mechanisms of ERK1/2 activation in MRdeficient mice, cardiac myocyte expression of upstream activators of ERK1/2 was assessed. Protein kinase C-␣ (Prkca) mRNA levels were 1. F4/80 (Emr1) 15, 16 did not reveal differences between genotypes ( Figure 4F and 4G).
Ablation of MR Expression in Fibroblasts
To investigate whether MRs in cardiac fibroblasts participate in cardiac remodeling after chronic pressure overload, the MR gene was also selectively deleted in fibroblasts using the regulatory elements of the collagen 1␣2 gene to drive Cre recombinase expression 20 (MR COLCre , Figure 5 and Figure S1 ). Ablation of MR mRNA expression in cardiac MR COLCre fibroblasts was confirmed by quantitative RT-PCR ( Figure 5A ). Ventricular weight indexes and cardiac function as determined by echocardiography did not differ between MR COLCre and control mice at baseline and after TAC (Figure 5B and 5C and Tables  S4 and S5 ). Importantly, pressure overload induced similar levels of interstitial and perivascular fibrosis in MR COLCre and in control mice ( Figure 5D through 5F). Expression of Nox2 and Emr1 mRNA did not differ between genotypes (Table   S6 ). Myocyte apoptosis induced by TAC did not differ significantly between genotypes (MR COLCre 82Ϯ25% of control; PϾ0.05; nϭ3 to 4 per genotype).
Discussion
The major finding of this study is that cell-specific ablation of the MR in cardiac myocytes but not in fibroblasts protects from ventricular dilatation and dysfunction after chronic pressure overload (Table) .
Validation of MR Ablation in Cardiac Myocytes
Cell-specific deletion of the exon 3 of the murine MR gene was verified by quantitative RT-PCR in myocyte and fibroblast cell fractions isolated from control, MR MLCCre , and MR COLCre mouse hearts, respectively. Cre-mediated recombination resulted in a reduction of MR mRNA levels in MR MLCCre myocytes by 89% and in MR COLCre fibroblasts by 98% as compared with the respective cell types isolated from control mice. The reduction in MR expression correlated well with the relative purity of the myocyte and fibroblast cell fractions as assessed by marker gene expression analysis for ␣-MHC or Ddr2, respectively (data not shown). Previous experiments have shown that Cremediated deletion of exon 3 of the MR gene leads to complete ablation of MR protein expression. 17, 25 In the murine heart, MR protein expression was too low for reliable detection by immunohistochemistry (data not shown). However, we demonstrated that targeted deletion of the MR gene in cardiac myocytes did not alter MR protein expression in the brain or kidney.
Cardiac Effects of Cell-Specific MR Ablation
In previous clinical and experimental studies, pharmacological blockade of MR has resulted in a significant protection of the heart from hypertrophy, fibrosis, and failure. and eplerenone were associated with a significant reduction in overall mortality of patients with chronic heart failure, in spite of the presence of inhibitors of the renin-angiotensin system. 1,2 These clinical findings have sparked a great research interest to identify mechanisms of cardioprotection, in particular for the antifibrotic effect conferred by MR antagonists. 9, 26 Cardiac myocyte-specific deletion of the MR gene prevented LV dilatation and failure after 20 weeks of chronic pressure overload. This finding is consistent with previous experimental evidence, including a recent report demonstrating that treatment with the MR antagonist eplerenone delayed the transition from compensated cardiac hypertrophy to dilatation and failure in mice 7 (Table) . We hypothesize that differences in the cardiac phenotype between MR MLCCre and wild-type mice at baseline may contribute to the protective effect of MR ablation during TAC. Loss of MR expression was accompanied by cardiac myocyte hypertrophy and distinct changes in gene expression in isolated myocytes at baseline. Myocyte hypertrophy in MR MLCCre mice at baseline may contribute to reduced wall stress during increased afterload. Reduced wall stress may thus prevent or delay the transition to failure and dilatation on chronic pressure overload. 27 After TAC, we found evidence for increased activation of ERK1/2 signaling in MR MLCCre hearts. Previous studies have linked activation of cardiac mitogen-activated protein kinase kinase 1-ERK1/2 signaling with the development of physiological hypertrophy and cardioprotection. 28, 29 Thus, ERK1/2 activation after TAC may prevent cardiac dilatation and failure after pressure overload. However, the mechanisms leading to ERK1/2 activation after MR deletion in cardiac myocytes still need to be uncovered in future studies.
Identification of the Cell Type Involved in Cardioprotection by MR Antagonists
Most recently 2 studies have reported the effects of specific MR ablation in macrophages on cardiac remodeling in mice. 15, 16 Together with the results from the present study, the relative contribution of cardiac cell types to the protective effects of MR antagonists may be assessed (Table) . For comparison, the study by Kuster et al 7 investigating the effects of eplerenone after LV pressure overload induced by constriction of the ascending aorta in mice may be used. In this model, eplerenone improved LV function and geometry and prevented dilatation, fibrosis, myocyte apoptosis, oxidative stress, macrophage infiltration, and inflammation. 7 In agreement with these results, we observed improved LV function and geometry and prevention of LV dilatation in MR MLCCre mice. Neither eplerenone 7 nor myocyte-specific MR ablation in the present study prevented cardiac hypertrophy after pressure overload. Interestingly, eplerenone-treated mice also showed a trend toward cardiac hypertrophy, which did not reach statistical significance. 7 In contrast to the study by Kuster et al, 7 interstitial and perivascular fibrosis as induced by pressure overload did not depend on cardiac myocyte or fibroblast MR in the present study. However, this observation is entirely consistent with findings from macrophage-specific MR deletion studies. 15, 16 MR ablation in macrophages significantly reduced cardiac fibrosis as induced by N G -nitro-L-arginine methyl ester/angiotensin II 16 or deoxycorticosterone acetate/salt treatment. 15 A classic MR target gene in epithelial cells, serum glucocorticoid-inducible kinase (Sgk1) 30 was downregulated to Ͻ15% of the expression level in control myocytes. Constitutive germline knockout of Sgk in mice led to reduced hypertrophy and fibrosis after deoxycorticosterone acetate/ 
Conclusions
Taken together, the present study demonstrates that ablation of MRs in cardiac myocytes but not in fibroblasts protects from dilatation and failure after chronic pressure overload. Selective ablation of MR expression in other cardiac cell types, including endothelial and vascular smooth muscle cells, will help to uncover the cellular and molecular mechanisms of cardioprotection conferred by MR antagonists.
Perspectives
Antagonists of the MR, like spironolactone and eplerenone, improve morbidity and mortality in patients with severe heart failure. Recently, ablation of MR in macrophages was reported to reduce the development of cardiac inflammation, hypertrophy, and fibrosis. To identify whether additional cell types in the heart are involved in the cardioprotective effects of MR inhibition after chronic cardiac pressure overload, the MR gene was selectively deleted in cardiac myocytes or fibroblasts of transgenic mice. Ablation of MR expression in myocytes but not in fibroblasts protected from LV dilatation and dysfunction. Thus, inhibition of MR function in cardiac myocytes and in macrophages may be essential for the cardioprotective effects of MR antagonists. These findings provide an essential basis for future studies to unravel the intracellular pathways involved in the beneficial effects of MR inhibition.
Lother, Cardiac mineralocorticoid receptors 1 
Supplemental material ABLATION OF MINERALOCORTICOID RECEPTORS IN MYOCYTES BUT NOT IN FIBROBLASTS PRESERVES CARDIAC FUNCTION AFTER CHRONIC PRESSURE OVERLOAD
Methods
Histology
Hearts were fixed with 4% paraformaldehyde in phosphate-buffered saline, embedded in paraffin and stained with hematoxylin-eosin, Sirius Red or wheat germ agglutinin and analyzed by morphometry 1, 2 . For immunohistochemical analysis, fixed coronal brain sections (50 µm) or kidney paraffin sections (7 µm) were stained using a monoclonal anti-MR antibody (rMR 1-18 1D5) 3, 4 . TUNEL staining was performed using the 'In situ cell death detection kit Fluorescein' (Roche) according to manufacturer's instructions. TUNEL-positive cells and total number of cells as determined by propidium iodide staining were determined in four randomly selected low-power fields per left ventricular section.
Isolation and culture of cardiac myocytes and fibroblasts
Mice were treated with 500 U heparin i.p. 15 min before cervical dislocation. Hearts were perfused for 20 min at 5 ml/min with enzyme solution containing 3 mg/ml collagenase type II (294 U/mg, Worthington), 126 mM NaCl, 4.4 mM KCl, 1 mM MgCl 2 , 4 mM NaHCO 3 , 10 mM HEPES, 11 mM glucose and 30 mM 2,3-butanedione monoxime, maintained at 37°C and saturated with carbogen 5, 6 . Cardiac myocytes were separated from non-myocytes by centrifugation in buffer containing 2% bovine serum albumine fraction V (Sigma). Myocytes were cultivated overnight in serum-free M-199 media (Sigma). Non-myocytes settled within 3h on petri dishes coated with 1% gelatin. For isolation of cardiac fibroblasts, ventricular tissue was cut into small pieces, transferred into tissue culture dishes and fibroblasts were allowed to grow out of these cultures for 7-10 days before further passaging and investigation 7 .
Gene expression analysis
Total RNA was prepared from isolated cells or ventricle samples with the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and its quality was assessed on RNA LabChips (Agilent, Santa Clara, CA, USA). Microarray experiments were carried out using GeneChip Mouse Genome 430A 2.0 arrays (Affymetrix, Santa Clara, CA, USA). Labeling of the target RNAs, hybridization and scanning of the microarrays were performed according to manufacturer's instruction. Data were analyzed using ArrayAssist 5.0 software (Stratagene). Probe levels were calculated using the GCRMA (GC Robust Multi-array Average) algorithm 8 . Quantitative real-time polymerase chain reaction was carried out as described previously 1, 2 . Primer sequences are listed in Supplemental Table S7 .
Protein phosphorylation analysis
Western blots to assess protein levels of total and phosphorylated forms of p70S6 kinase (1:1000, Cell Signaling Technology, phospho-Thr421/Ser424), Akt (1:1000, Cell Signaling Technology), phospho-Akt (1:200, Ser473, Santa Cruz Biotechnology, Inc.), ERK1/2 (1:1000, Cell Signaling Technology, phospho-Thr202/Tyr204), p38 (1:1000, Cell Signaling Technology, phospho-Thr180/Tyr182), Stat3 (1:1000, Cell Signaling Technology, phospho-Ser727/Tyr705), JNK1,2,3 (1:1000, Cell Signaling Technology, phospho-Thr183/Tyr185) were performed using protein extracts from mouse hearts. Proteins (20 µg) were fractioned by 12.5% sodium dodecyl sulphatepolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes where incubated over night at 4°C with the primary antibodies, followed by one hour incubation with the secondary antibodies, processed with a Fuji Film LAS-3000 (Fuji Film) and analyzed with MultiGauge software (Fuji Film). 
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